Skip to search formSkip to main contentSkip to account menu

lumretuzumab

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

RG7116

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy
Combination of targeted therapies is expected to provide superior efficacy in the treatment of cancer either by enhanced… 
2018
2018
Abstract 3989: Dual targeting of ErbB2/ErbB3 for treatment of SCL3A2-NRG1-mediated lung cancer
We previously identified an oncogenic fusion gene involving the 5′ region of SLC3A2 and the 3′ region of NRG1 in a patient with… 
2017
2017
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab
AbstractPurposeThis study aimed at evaluating if pharmacokinetic and pharmacodynamic data from the first few patients treated… 
2017
2017
Abstract P6-11-13: Phase Ib study evaluating the safety and clinical activity of lumretuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer
Background: Inhibition of HER2 and HER3 heterodimerisation is a novel treatment concept in HER2-”low” expressing breast cancer… 
2016
2016
Impact of tumor heregulin mRNA expression on outcome of patients with advanced/metastatic squamous NSCLC treated with lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)